1. Home
  2. GLUE vs BWMX Comparison

GLUE vs BWMX Comparison

Compare GLUE & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • BWMX
  • Stock Information
  • Founded
  • GLUE 2019
  • BWMX 1995
  • Country
  • GLUE United States
  • BWMX Mexico
  • Employees
  • GLUE N/A
  • BWMX N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • BWMX Catalog/Specialty Distribution
  • Sector
  • GLUE Health Care
  • BWMX Consumer Discretionary
  • Exchange
  • GLUE Nasdaq
  • BWMX Nasdaq
  • Market Cap
  • GLUE 475.5M
  • BWMX 553.8M
  • IPO Year
  • GLUE 2021
  • BWMX N/A
  • Fundamental
  • Price
  • GLUE $8.46
  • BWMX $12.13
  • Analyst Decision
  • GLUE Buy
  • BWMX Strong Buy
  • Analyst Count
  • GLUE 3
  • BWMX 1
  • Target Price
  • GLUE $14.67
  • BWMX $22.50
  • AVG Volume (30 Days)
  • GLUE 6.1M
  • BWMX 28.8K
  • Earning Date
  • GLUE 11-07-2024
  • BWMX 10-24-2024
  • Dividend Yield
  • GLUE N/A
  • BWMX 11.17%
  • EPS Growth
  • GLUE N/A
  • BWMX N/A
  • EPS
  • GLUE N/A
  • BWMX 1.21
  • Revenue
  • GLUE $14,975,000.00
  • BWMX $700,821,742.00
  • Revenue This Year
  • GLUE N/A
  • BWMX $9.30
  • Revenue Next Year
  • GLUE N/A
  • BWMX $6.59
  • P/E Ratio
  • GLUE N/A
  • BWMX $9.88
  • Revenue Growth
  • GLUE N/A
  • BWMX 6.88
  • 52 Week Low
  • GLUE $2.91
  • BWMX $11.67
  • 52 Week High
  • GLUE $12.40
  • BWMX $21.28
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 54.20
  • BWMX 42.06
  • Support Level
  • GLUE $7.40
  • BWMX $11.67
  • Resistance Level
  • GLUE $8.62
  • BWMX $12.81
  • Average True Range (ATR)
  • GLUE 0.79
  • BWMX 0.40
  • MACD
  • GLUE -0.21
  • BWMX -0.04
  • Stochastic Oscillator
  • GLUE 29.50
  • BWMX 29.11

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About BWMX Betterware de Mexico S.A.P.I. de C.V.

Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.

Share on Social Networks: